Patents by Inventor Justin Andrew Caravella

Justin Andrew Caravella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulator
    Patent number: 11879008
    Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: January 23, 2024
    Assignee: Q32 Bio Inc.
    Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
  • Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors
    Patent number: 11814386
    Abstract: The disclosure relates to USP30 Inhibitor Compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same.
    Type: Grant
    Filed: October 20, 2022
    Date of Patent: November 14, 2023
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Alex J. Buckmelter, Justin Andrew Caravella, Hongbin Li, Matthew W. Martin, Steven Mischke, David James Richard, Angela V. West
  • FUSED PYRROLINES WHICH ACT AS UBIQUITIN-SPECIFIC PROTEASE 30 (USP30) INHIBITORS
    Publication number: 20230126252
    Abstract: The disclosure relates to USP30 Inhibitor Compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same.
    Type: Application
    Filed: October 20, 2022
    Publication date: April 27, 2023
    Inventors: Alex J. Buckmelter, Justin Andrew Caravella, Hongbin Li, Matthew W. Martin, Steven Mischke, David James Richard, Angela V. West
  • PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
    Publication number: 20230125739
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
    Type: Application
    Filed: November 9, 2022
    Publication date: April 27, 2023
    Applicant: FORMA Therapeutics, Inc.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors
    Patent number: 11535618
    Abstract: The disclosure relates to USP30 Inhibitor Compounds I, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: December 27, 2022
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Alex J. Buckmelter, Justin Andrew Caravella, Hongbin Li, Matthew W. Martin, Steven Mischke, David James Richard, Angela V. West
  • Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
    Patent number: 11498913
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: November 15, 2022
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS
    Publication number: 20220281869
    Abstract: The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula: where R1, R2, R3, R3?, R4, R5, X1, X2, X3, X4, and n are described herein.
    Type: Application
    Filed: September 30, 2021
    Publication date: September 8, 2022
    Inventors: Alexandre Joseph Buckmelter, Stephanos Ioannidis, Bruce Follows, Gary Gustafson, Minghua Wang, Justin Andrew Caravella, Zhongguo Wang, Edward L. Fritzen, Jian Lin
  • COMPOSITIONS FOR INHIBITING UBIQUITIN SPECIFIC PROTEASE 1
    Publication number: 20220073525
    Abstract: This disclosure relates to modulating ubiquitin specific protease 1 (USP1) and provides novel chemical compounds useful as inhibitors of USP1, as well as various uses of these compounds. USP1 inhibiting compounds are useful in the treatment of diseases and disorders associated with USP1, such as cancer.
    Type: Application
    Filed: December 27, 2019
    Publication date: March 10, 2022
    Applicant: FORMA Therapeutics, Inc.
    Inventors: Alexandre Joseph Buckmelter, Justin Andrew Caravella, Jian Lin, Edward L. Fritzen
  • FUSED PYRROLINES WHICH ACT AS UBIQUITIN-SPECIFIC PROTEASE 30 (USP30) INHIBITORS
    Publication number: 20210355126
    Abstract: The disclosure relates to USP30 Inhibitor Compounds I, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same.
    Type: Application
    Filed: October 4, 2019
    Publication date: November 18, 2021
    Inventors: Alex J. Buckmelter, Justin Andrew Caravella, Hongbin Li, Matthew W. Martin, Steven Mischke, David James Richard, Angela V. West
  • PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS
    Publication number: 20210332052
    Abstract: The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X1, X2, R1-R5, R5? and R6 are described herein.
    Type: Application
    Filed: February 26, 2021
    Publication date: October 28, 2021
    Inventors: Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Buckmelter, Minghua Wang, Ann-Marie Campbell, Darby Rye Schmidt, David Joseph Guerin, Justin Andrew Caravella, R. Bruce Diebold, Anna Ericsson, David R. Lancia, JR.
  • FUSION PROTEIN CONSTRUCTS FOR COMPLEMENT ASSOCIATED DISEASE
    Publication number: 20210309728
    Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
    Type: Application
    Filed: June 4, 2021
    Publication date: October 7, 2021
    Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
  • Fusion protein constructs comprising anti-C3d antibody and CR1 polypeptide
    Patent number: 11053305
    Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: July 6, 2021
    Assignee: Q32 Bio Inc.
    Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
  • Fusion protein constructs comprising anti-C3d antibody and factor H
    Patent number: 11053306
    Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: July 6, 2021
    Assignee: Q32 Bio Inc.
    Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
  • PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
    Publication number: 20210078973
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 18, 2021
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
    Patent number: 10934299
    Abstract: The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X1, X2, R1-R5, R5? and R6 are described herein.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: March 2, 2021
    Assignee: Valo Early Discovery, Inc.
    Inventors: Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Buckmelter, Minghua Wang, Ann-Marie Campbell, Darby Rye Schmidt, David Joseph Guerin, Justin Andrew Caravella, R. Bruce Diebold, Anna Ericsson, David R. Lancia, Jr.
  • FUSION PROTEIN CONSTRUCTSCOMPRISING ANTI-C3d ANTIBODY AND FACTOR H
    Publication number: 20210009669
    Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
    Type: Application
    Filed: September 29, 2020
    Publication date: January 14, 2021
    Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
  • Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
    Patent number: 10889567
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: January 12, 2021
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
    Patent number: 10807976
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where Y1, X1, X2, Y2, W1, W2, W3, and R1-R5 are described herein.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: October 20, 2020
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
    Publication number: 20200223822
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
    Type: Application
    Filed: December 12, 2019
    Publication date: July 16, 2020
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • FUSION PROTEIN CONSTRUCTS FOR COMPLEMENT ASSOCIATED DISEASE
    Publication number: 20200181249
    Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
    Type: Application
    Filed: January 24, 2020
    Publication date: June 11, 2020
    Inventors: MICHAEL STEVEN CURTIS, MICHAEL STOREK, SHELIA MARIE VIOLETTE, SUSAN L. KALLED, KELLY C. FAHNOE, CHENG RAN HUANG, ELLEN GARBER STARK, FREDERICK ROBBINS TAYLOR, JUSTIN ANDREW CARAVELLA, VERNON MICHAEL HOLERS